SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-24-005220
Filing Date
2024-02-07
Accepted
2024-02-07 13:06:39
Documents
15
Period of Report
2024-02-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 45766
  Complete submission text file 0001493152-24-005220.txt   266454

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE cldi-20240207.xsd EX-101.SCH 3813
3 XBRL DEFINITION FILE cldi-20240207_def.xml EX-101.DEF 26683
4 XBRL LABEL FILE cldi-20240207_lab.xml EX-101.LAB 36817
5 XBRL PRESENTATION FILE cldi-20240207_pre.xml EX-101.PRE 25307
16 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5881
Mailing Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121 858-794-9600
Calidi Biotherapeutics, Inc. (Filer) CIK: 0001855485 (see all company filings)

IRS No.: 862967193 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40789 | Film No.: 24603442
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)